Case Analysis – Asian Woman with Bipolar Disorder. – 1 to 2 pages

Bipolar TherapyClient of Korean Descent/AncestryBACKGROUND INFORMATIONThe client is a 26-year-old woman of Korean descent who presents to her first appointment following a 21-day hospitalization for onset of acute mania. She was diagnosed with bipolar I disorder.Upon arrival in your office, she is quite “busy,” playing with things on your desk and shifting from side to side in her chair. She informs you that “they said I was bipolar, I don’t believe that, do you? I just like to talk, and dance, and sing. Did I tell you that I liked to cook?”She weights 110 lbs. and is 5’ 5”SUBJECTIVEPatient reports “fantastic” mood. Reports that she sleeps about 5 hours/night to which she adds “I hate sleep, it’s no fun.”You reviewed her hospital records and find that she has been medically worked up by a physician who reported her to be in overall good health. Lab studies were all within normal limits. You find that the patient had genetic testing in the hospital (specifically GeneSight testing) as none of the medications that they were treating her with seemed to work.Genetic testing reveals that she is positive for CYP2D6*10 allele.Patient confesses that she stopped taking her lithium (which was prescribed in the hospital) since she was discharged two weeks ago.MENTAL STATUS EXAMThe patient is alert, oriented to person, place, time, and event. She is dressed quite oddly- wearing what appears to be an evening gown to her appointment. Speech is rapid, pressured, tangential. Self-reported mood is euthymic. Affect broad. Patient denies visual or auditory hallucinations, no overt delusional or paranoid thought processes readily apparent. Judgment is grossly intact, but insight is clearly impaired. She is currently denying suicidal or homicidal ideation.The Young Mania Rating Scale (YMRS) score is 22RESOURCES§ Chen, R., Wang, H., Shi, J., Shen, K., & Hu, P. (2015). Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems. European Journal of Clinical Pharmacology, 71(7), 835-841. doi:10.1007/s00228-015-1855-6Decision Point OneSelect what the PMHNP should do:Begin Lithium 300 mg orally BIDBegin Risperdal 1 mg orally BIDBegin Seroquel XR 100 mg orally at HSExamine Case Study: An Asian American Woman With Bipolar Disorder. You will be asked to make three decisions concerning the medication to prescribe to this client. Be sure to consider factors that might impact the client’s pharmacokinetic and pharmacodynamic processes.At each decision point stop to complete the following:Decision #1Which decision did you select?Why did you select this decision? Support your response with evidence and references to the Learning Resources.What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources.Explain any difference between what you expected to achieve with Decision #1 and the results of the decision. Why were they different?Decision #2Why did you select this decision? Support your response with evidence and references to the Learning Resources.What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources.Explain any difference between what you expected to achieve with Decision #2 and the results of the decision. Why were they different?Decision #3Why did you select this decision? Support your response with evidence and references to the Learning Resources.What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources.Explain any difference between what you expected to achieve with Decision #3 and the results of the decision. Why were they different?Also include how ethical considerations might impact your treatment plan and communication with clients.Choice one: I choose to start SeroquelDecision Point OneBegin Seroquel XR 100 mg orally at HSRESULTS OF DECISION POINT ONEClient returns to clinic in four weeksClient is reporting that she sleeps a bit more at bedtimeClient states that she has gained about 2 or 3 pounds, which she does not likeClient also reports that she has been constipated since starting this medicationClient is also complaining of dry mouth which she does not like.Client’s score on the Young Mania Rating Scale has decreased from a 22 to an 18Client is reporting really good mood, but is asking for a different medication because of the weight gainDecision Point TwoSelect what the PMHNP should do next:Increase Seroquel XR to 300 mg orally dailyDiscontinue Seroquel and start Geodon 40 mg orally BID. Administer with 500 calorie mealContinue same dose of Seroquel and counsel client regarding ways to prevent constipationI choose to discontinue Seroquel and start Geodon 40 mg orally BID. ADminister with 500 calorie mealDiscontinue Seroquel and start Geodon 40 mg orally BID. Administer with 500 calorie mealRESULTS OF DECISION POINT TWOClient returns to clinic in four weeksClient demonstrates a 50% decrease in score on the Young Mania Rating Scale (from 22 to 11)Client denies any additional weight gain and denies any additional side effectsDecision Point ThreeSelect what the PMHNP should do next:Continue same dose and reassess in 4 weeksIncrease Geodon to 60 mg orally BID with a 500 calorie mealAugment with Lithium sustained release 300 mg orally BIDI now choose to continue same dose and reassess in 4 weeksDecision Point ThreeContinue same dose and reassess in 4 weeksGuidance to StudentThe PMHNP should provide counseling to the client about this side effect and encourage increased fluids and fiber in the diet to combat constipation. Hard candies or gum can be used to prevent dry mouth. This is another issue as the drug can cause dental problems as a result of dry mouth.Changing to Geodon clearly helped with symptoms and arrested weight gain in this client. The PMHNP could wait 4 weeks and see if any changes in Young Mania Rating Scale are noted, or increasing to 60 mg orally BID in an attempt to hasten symptom improvement. Increasing dose may be associated with side effects.Augmentation with Lithium may be appropriate if the goal of therapy is to discontinue antipsychotic therapy and treat with Lithium monotherapy. Lithium was problematic for this client but changing formulation to the extended release may overcome the difficulties she was experiencing with side effects. The PMHNP would need to educate client regarding side effects of medication and need to maintain compliance.

 

Do you need a similar assignment done for you from scratch? We have qualified writers to help you. We assure you an A+ quality paper that is free from plagiarism. Order now for an Amazing Discount!
Use Discount Code "Newclient" for a 15% Discount!

NB: We do not resell papers. Upon ordering, we do an original paper exclusively for you.